Celltrion Pharmaceutical achieved record revenue and operating profit for the third quarter of this year.
On November 9, Celltrion announced that its third-quarter revenue reached 161.9 billion won, a 17.2% increase compared to the same period last year, while operating profit rose by 48.4% to 23.9 billion won. The operating profit margin for the quarter was 14.8%, up 3.1 percentage points from the previous year.
For the cumulative third-quarter results, revenue increased by 17.1% to 447.3 billion won, and operating profit grew by 32.4% to 56.1 billion won. The net profit for the period was 40.2 billion won, reflecting a 34.6% increase from the same time last year.
Celltrion attributed its strong performance to stable sales of chemical drugs, an increase in prescriptions for biopharmaceuticals at major hospitals, and maximum operation of its pre-filled syringe (PFS) production facilities.
The company stated, "We plan to continue the growth momentum across all business sectors through the end of the year, aiming for significant annual results."
On November 9, Celltrion announced that its third-quarter revenue reached 161.9 billion won, a 17.2% increase compared to the same period last year, while operating profit rose by 48.4% to 23.9 billion won. The operating profit margin for the quarter was 14.8%, up 3.1 percentage points from the previous year.
For the cumulative third-quarter results, revenue increased by 17.1% to 447.3 billion won, and operating profit grew by 32.4% to 56.1 billion won. The net profit for the period was 40.2 billion won, reflecting a 34.6% increase from the same time last year.
Celltrion attributed its strong performance to stable sales of chemical drugs, an increase in prescriptions for biopharmaceuticals at major hospitals, and maximum operation of its pre-filled syringe (PFS) production facilities.
The company stated, "We plan to continue the growth momentum across all business sectors through the end of the year, aiming for significant annual results."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.